Drugs & Targets FDA approves Ibtrozi oral treatment for advanced ROS1+ NSCLC June 13, 2025Vol.51 No.23
Cancer Policy FDA booth stood empty at 2025 ASCO annual meeting June 06, 2025Vol.51 No.22By Jacquelyn Cobb
Cancer Policy Makary: Level of evidence is an artificial and dogmatic construct June 06, 2025Vol.51 No.22By Jacquelyn Cobb
Drugs & Targets FDA approves Nubeqa for metastatic castration-sensitive prostate cancer June 06, 2025Vol.51 No.22
Drugs & Targets FDA grants priority review for sevabertinib in HER2-mutant NSCLC May 30, 2025Vol.51 No.21
Drugs & Targets Alligator Bioscience announces European orphan drug designation for HLX22 in gastric cancer May 30, 2025Vol.51 No.21
Regulatory News ODAC marathon: Committee charges through a pileup of clinical questions in a two-day, four-application session May 23, 2025Vol.51 No.20By Jacquelyn Cobb
Cancer Policy FDA Commissioner Makary holds roundtable discussion on harms of talc May 23, 2025Vol.51 No.20By Claire Marie Porter
